Evicenter
MarkdownMedical informationP&T meetings
Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Launch
Not announced
Last updated
62 sources

Section 6 of 6

References

62 sources

  1. American Cancer Society (2026) (opens in a new tab)
  2. ASCO (2022) (opens in a new tab)
  3. ASCO (2023) (opens in a new tab)
  4. Ashouri et al. (2025) (opens in a new tab)
  5. Bhimani et al. (2022) (opens in a new tab)
  6. Blank et al. (2011) (opens in a new tab)
  7. Burge et al. (2026) (opens in a new tab)
  8. Cann et al. (2026) (opens in a new tab)
  9. Cayman Chemical (2025) (opens in a new tab)
  10. Centers for Disease Control and Prevention about colorectal cancer page (opens in a new tab)
  11. Centers for Disease Control and Prevention colorectal cancer risk factors page (opens in a new tab)
  12. Centers for Disease Control and Prevention colorectal cancer symptoms page (opens in a new tab)
  13. Dasari et al. (2023) (opens in a new tab)
  14. Dauki et al. (2026) (opens in a new tab)
  15. Eng et al. (2019) (opens in a new tab)
  16. EU Clinical Trials Register EudraCT 2021-003243-21 (opens in a new tab)
  17. Exelixis access to investigational therapies policy (opens in a new tab)
  18. Exelixis clinical trials pipeline (opens in a new tab)
  19. Exelixis first quarter 2026 Form 10-Q (2026) (opens in a new tab)
  20. Exelixis Form 10-K (2026) (opens in a new tab)
  21. Exelixis Form 8-K (2026) (opens in a new tab)
  22. Exelixis new drug application acceptance announcement (2026) (opens in a new tab)
  23. Exelixis second quarter 2026 Form 10-Q (2026) (opens in a new tab)
  24. Exelixis STELLAR-001 results announcement (2025) (opens in a new tab)
  25. Exelixis STELLAR-303 detailed results announcement (2025) (opens in a new tab)
  26. Exelixis STELLAR-303 healthcare professional brochure (2023) (opens in a new tab)
  27. Exelixis STELLAR-303 topline results announcement (2025) (opens in a new tab)
  28. Exelixis STELLAR-303 update announcement (2026) (opens in a new tab)
  29. FDA (2026) (opens in a new tab)
  30. FDA fruquintinib approval announcement (2023) (opens in a new tab)
  31. FDA nivolumab with ipilimumab approval announcement (2025) (opens in a new tab)
  32. FDA sotorasib with panitumumab approval announcement (2025) (opens in a new tab)
  33. FDA trifluridine and tipiracil with bevacizumab approval announcement (2023) (opens in a new tab)
  34. FDA tucatinib with trastuzumab accelerated approval announcement (2023) (opens in a new tab)
  35. Fontana et al. (2025) (opens in a new tab)
  36. Garmezy et al. (2025) (opens in a new tab)
  37. Grothey et al. (2013) (opens in a new tab)
  38. Guven et al. (2024) (opens in a new tab)
  39. Hecht et al. (2025) (opens in a new tab)
  40. Hsu et al. (2021) (opens in a new tab)
  41. Hsu et al. (2023) (opens in a new tab)
  42. Kawazoe et al. (2024) (opens in a new tab)
  43. Kiel et al. (2026) (opens in a new tab)
  44. Morris et al. (2022) (opens in a new tab)
  45. National Cancer Institute Colon Cancer Treatment PDQ (opens in a new tab)
  46. National Cancer Institute Drug Dictionary (opens in a new tab)
  47. National Cancer Institute SEER Cancer Stat Facts (opens in a new tab)
  48. Paly et al. (2024) (opens in a new tab)
  49. Patnaik et al. (2021) (opens in a new tab)
  50. Prager et al. (2023) (opens in a new tab)
  51. Rasschaert and Tejpar (2025) (opens in a new tab)
  52. Saeed et al. (2024a) (opens in a new tab)
  53. Saeed et al. (2024b) (opens in a new tab)
  54. Saeed et al. (2025) (opens in a new tab)
  55. Shankaran et al. (2022) (opens in a new tab)
  56. Sharma et al. (2022) (opens in a new tab)
  57. Stintzing et al. (2025) (opens in a new tab)
  58. Strohbehn et al. (2026) (opens in a new tab)
  59. Taieb et al. (2025) (opens in a new tab)
  60. Yoshino et al. (2023) (opens in a new tab)
  61. Yoshino et al. (2023) (opens in a new tab)
  62. Yu et al. (2024) (opens in a new tab)